Gurnet Point Capital

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.

Naveris Inc. is a biotechnology company specializing in the development of sensitive blood tests for early cancer detection, which enhances patient outcomes. Founded in 2017 and based in Waltham, Massachusetts, Naveris offers NavDx, a blood test that identifies human papilloma virus-associated cancers by quantifying tumor-specific DNA fragments released into the bloodstream. The company's innovative biomimetic technology simulates the complexities of human tissues and tumors, facilitating early diagnosis in asymptomatic individuals, real-time monitoring of treatment responses, and the detection of cancer recurrence in patients in remission. Naveris aims to improve oncology clinical trials and precision medicine, ensuring that therapies are effectively matched to individual patients.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Fairtility specializes in enhancing in-vitro fertilization (IVF) processes through the application of artificial intelligence and big data. The company has developed an AI-powered decision support system that focuses on accurate embryo classification and implantation prediction. By leveraging computer vision algorithms, Fairtility's platform aims to improve the efficiency of IVF treatments, thereby reducing the time required to achieve a live birth. This technology provides patients with timely and data-driven assessments of embryo quality, ultimately leading to higher pregnancy rates and minimizing the number of IVF cycles needed.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Naveris Inc. is a biotechnology company specializing in the development of sensitive blood tests for early cancer detection, which enhances patient outcomes. Founded in 2017 and based in Waltham, Massachusetts, Naveris offers NavDx, a blood test that identifies human papilloma virus-associated cancers by quantifying tumor-specific DNA fragments released into the bloodstream. The company's innovative biomimetic technology simulates the complexities of human tissues and tumors, facilitating early diagnosis in asymptomatic individuals, real-time monitoring of treatment responses, and the detection of cancer recurrence in patients in remission. Naveris aims to improve oncology clinical trials and precision medicine, ensuring that therapies are effectively matched to individual patients.

Tremeau Pharmaceuticals, based in Concord, Massachusetts, specializes in the development and manufacturing of non-opioid pain therapies aimed at individuals with rare diseases. The company focuses on conditions that are significantly affected by the cyclooxygenase (COX) and prostanoid pathways, addressing high unmet medical needs in orphan disease states. Among its products are TRM-201, a COX-2 selective nonsteroidal anti-inflammatory drug designed for hemophilic arthropathy, and TRM-359. Tremeau's therapies are designed to manage both acute and chronic pain while offering a clinically differentiated profile that provides therapeutic advantages over traditional opioid treatments. Founded in 2007, Tremeau Pharmaceuticals is committed to providing innovative solutions for patients with bleeding concerns and painful inflammatory conditions.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Corium Innovations is a contract development and manufacturing organization that specializes in novel drug delivery technologies. The company focuses on providing comprehensive support throughout the entire process, from formulation and product development to commercial-scale manufacturing and packaging. By partnering with clients, Corium Innovations helps in the development and production of innovative drug delivery solutions, ensuring that its clients can effectively bring their products to market.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

Innocoll is a privately held biopharmaceutical company specializing in collagen-based pharmaceutical products and medical devices. The company develops biodegradable surgical implants and topically applied healthcare solutions aimed at enhancing patient care in various medical contexts. Its product lineup includes CollaGUARD, a bioresorbable collagen film to prevent post-operative adhesions, and Collatamp Gentamicin, which helps treat or prevent surgical infections. Septocoll serves as a dual-action sponge for infection management, while RegenePro is designed for dental applications. Innocoll is also advancing product candidates like XaraColl, currently in phase III trials for post-operative pain relief, and Cogenzia, aimed at diabetic foot infections. With its headquarters in Athlone, Ireland, Innocoll utilizes a proprietary technology platform to create products that are fully bioresorbable, offering non-opioid alternatives for pain management in surgical settings.

BEFORE Brands, Inc. is a science-based consumer products company based in Menlo Park, California, focused on providing nutritional products aimed at supporting the health and wellness of families, particularly infants. Established in 2015, the company develops edible products utilizing its proprietary Early Adaptive Tolerance technology, which combines whole food proteins and vitamin D to offer balanced, gentle, and consistent immune system support. This innovative approach, developed by Dr. Kari Nadeau, a pediatrician and director at the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, emphasizes the importance of integrating potentially allergenic foods into a healthy diet from an early age. By targeting immune system training in infants, BEFORE Brands aims to address the disruptions caused by modern living and promote long-term health.

Crossover Health, Inc. provides comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010, the company is headquartered in Aliso Viejo, California, with health centers located in various regions, including Silicon Valley. Crossover Health offers a wide range of services, including primary care, urgent care, chronic disease management, preventive care, health risk assessments, and health education. Additionally, it provides ancillary services such as physical therapy, chiropractic care, acupuncture, and care coordination, along with health analytics and remote care options. The company's focus is on creating a positive employee care experience that promotes a healthy and motivated workforce while delivering financial benefits to organizations.

Auregen BioTherapeutics is a biotechnology company focused on developing innovative treatments for rare disorders, particularly congenital craniofacial conditions. The company specializes in 3D bioprinting technology and rare disease cell therapy, aiming to create effective solutions for patients with these challenging medical issues. By leveraging advanced bioprinting techniques, Auregen seeks to explore new treatment options that could significantly improve the quality of life for individuals affected by rare diseases.

Amazentis SA is a life science company based in Lausanne, Switzerland, founded in 2007. The company specializes in the research and development of bioactive ingredients aimed at advanced therapeutic nutrition, particularly for the aging population. Amazentis focuses on creating products that enhance mitochondrial health, addressing age-related muscle decline by improving mitochondrial activity. Utilizing proprietary technology, the company mimics the effects of certain foods, like pomegranates, to repair damage in mitochondria and promote an active lifestyle. Through its innovative approach, Amazentis aims to meet specific health needs, particularly in hospital settings, by optimizing muscle function and overall well-being.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.